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Summary Paragangliomas of the head and neck (glomus tumours) can occur in a hereditary pattern and may
be hormonally active as well as being associated with paragangliomas elsewhere. A number of these tumours
may be present without symptoms. To detect the presence of subclinical paragangliomas we screened 83
members of a family at risk of developing hereditary paragangliomas using whole body MRI and urinary
catecholamine testing. In eight previously diagnosed members, eight known glomus tumours of which one
functioning, and two unknown glomus tumours and one unknown pheochromocytoma were present. Six
unsuspected members showed ten glomus tumours and one pheochromocytoma. It has been suggested that the
manifestation ofhereditary glomus tumours is determined by the sex of the transmitting parent. There were no
tumours in the descendants of female gene carriers. Comparing the likelihood of inheritance with genomic
imprinting versus inheritance without genomic imprinting we found an odds ratio of 23375 in favour of
genomic imprinting.
Parangliomas of the head and neck region, also known as
glomus tumours or chemodectomas, arise from paragan-
glionic tissue at the carotid bifurcation and in the jugular
fossa, the middle ear and the superior mediastinum. Together
with the aortico-sympathetic, visceral-autonomic and intra-
vagal paragangliomas and adrenal pheochromocytomas they
form a class of tumours known as paragangliomas (Glenner
& Grimley, 1974). At least 30% of glomus tumours are
familial in origin. Multiple tumours occur in approximately
25 to 35% of patients with familial disease but in less than
5% of those with the non-familial type (Grufferman et al.,
1980). Several authors have found the hereditary pattern of
familial glomus tumours to be autosomal dominant (Gruffer-
man et al., 1980; Parkin, 1981). Recently, however, during a
retrospective analysis of medical records from 15 affected
pedigrees, our group found that the clinical manifestation of
the disease is determined by the sex of the transmitting
parent (van der Mey et al., 1989). Children of female gene
carriers never showed tumour growth, while the prevalence in
offspring of male gene carriers increased with age to the
expected 50% for an autosomal dominant disorder. This
finding can be explained by genomic imprinting, i.e. the
maternally derived gene is inactivated during o6genesis and
can only be reactivated during spermatogenesis. For several
disorders including Huntington's disease and myotonic dys-
trophy, this new concept has been suggested as a possible
explanation for differences in clinical presentation, age of
onset and severity that seem to be related to the parental
origin of the disease gene. Its suggested role in carcinogenesis
is supported by the finding that deletions or losses of
chromosome 11 that occur in sporadic cases of Wilms
tumour almost always involve the chromosome of maternal
origin (Hall, 1990). Paragangliomas are potentially capable of
catecholamine production. The proportion of catecholamine
secreting paragangliomas is thought to be high for adrenal
pheochromocytomas, intermediate for aortico-sympathetic
and visceral-autonomic paragangliomas and low for
paragangliomas of the head and neck region (Dunn et al.,
1986). We previously reported that the prevalence of hor-
monally active glomus tumours and their association with
other paragangliomas in non-familial cases might be well
higher than has been previously suspected (van Gils et al.,
1990).
Initially, paragangliomas are often small and extremely
slow-growing and hardly cause symptoms. As a result of this
indolent growth pattern, the number of affected relatives and
the percentage of hormonally active tumours may well have
been underestimated in the past. It is, however, important to
identify familial cases, as their offspring may also carry a
50% risk of developing tumours. Early identification of new
cases and of new lesions in a known patient is relevant since
glomus tumour growth may eventually lead to destruction of
adjacent stuctures and to harmful hormonal activity.
Magnetic resonance imaging (MRI) has been found very
effective in the detection of paragangliomas. Its good ana-
tomical resolution, the absence of radiation hazard, and the
redundancy of contrast media containing iodine make MRI
useful as a screening modality in patients suspected of having
these tumours (van Gils et al., 1991).
With these considerations and the above postulated new
genetic theory in mind we screened a large, representative
kindred group at risk of developing glomus tumours and
other paragangliomas, using MRI as a primary screening
tool. Free urinary catecholamines and vanillylmandelic acid
(VMA) levels were measured to detect endocrine-active les-
ions. The purpose of our study was to acquire greater cer-
tainty as to the true number of affected family members and
as to the number of lesions with endocrine activity by diag-
nosing all possible cases. Our extensive evaluation of this
unique family also enabled us to test the hypothesis that
tumour development only occurs in offspring of male gene
carriers. Detection of subclinical lesions in children of female
gene carriers would be inconsistent with the predictions ac-
cording to the genomic imprinting theory.
Patients and methods
Patients
Between January and December 1990, 90 members of a large
kindred group all aged above 18 years and at risk of develop-
ing paragangliomas were invited for screening. Two deceased
and eight living members had been previously diagnosed as
glomus tumour patients. Most relatives were resident in the
neighbourhood of our hospital which facilitated screening.
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Seven relatives declined to participate for various reasons. All
participants gave informed consent and the study was ap-
proved by the local ethics committee.
The screening program included a medical history, physical
and otolaryngological examination, whole body MRI and
determination of free urinary catecholamine excretion in all
subjects. Blood was collected from participating family mem-
bers for DNA linkage studies. For confirmation of glomus
tumours, contrast enhanced computed tomography (CT) or
angiography was performed. Where a hormonally active
lesion was suspected ['23I]MIGB scintigraphy was used. Clin-
ical information concerning deceased members of early gen-
erations of the kindred group was obtained from medical
records or death certificates. All individuals found to have
paragangliomas as well as their parents were classified as
obligate gene carriers.
Magnetic resonance imaging
Patients were examined at 1.5 T using a Gyroscan-SI5®
(Philips, Best, The Netherlands) scanner. In all cases a body
coil was used. Imaging technique included multisectional
acquisition of the head and neck area with 1 cm-thick trans-
verse slices, intersection gaps of approximately 1 mm, an
acquisition matrix of 179 x 256 and a display matrix of
256 x 256. The field of view was 240 mm. Patients were
examined with a spin echo sequence TR 2200/TE 30-80 and
a spin echo sequence TR 600/TE 20 before and after intra-
venous injection of 0.1 mmol kg-' Gadopentetate dimeg-
lumine (Magnevist® Schering, Berlin, Germany). After imag-
ing of the head and neck area, Ti and T2-weighted coronal
images of the abdomen and mediastinum were taken in two
series using a field of view of 500 mm. If this routine scan
was equivocal, a more meticulous examination of the area of
interest was carried out using transverse TI and T2-weighted
images. Total procedure time varied from 1.5 to 2 h. All
studies were reviewed independently by two investigators
(A.P.v.G., T.H.M.F.).
Computer tomography
Patients who had one or more chemodectomas in the head
and neck region on MRI were further investigated with
contrast enhanced CT using 6 mm thick adjacent coronal and
9 mm thick adjacent axial slices of the head and neck.
Catecholamine measurements
The urinary excretion of norepinephrine, epinephrine, dopa-
mine and vanillylmandelic acid was assessed in 24 h urine
samples collected on three consecutive days. Norepinephrine,
epinephrine and dopamine levels were assayed by high per-
formance liquid chromatography (HPLC) and electrochem-
ical detection (Coulochem 5100 A ESAR). VMA levels were
measured by colorimetry after paper chromatography.
Scintigraphy
Patients in whom elevated urinary catecholamine levels were
found underwent [231I]MIBG scintigraphy. A list of all drugs
recently used was obtained to rule out interference with
['231lMIBG uptake; special attention was paid to drugs such
as reserpine, tricyclic anti-depressants, phenylpropanolamine
and sympatholytic agents. Thyroidal uptake was blocked by
the administration of Lugol's solution, ten drops three times
daily (50 mg of iodine) for 5 days, starting the day before
injection. Each patient was injected intravenously with 370
MBq ['231]MIBG while in the supine position.
Anterior and posterior digitised images of the total body
and four images of the head and neck were obtained 24 h
and 48 h after injection. Additional single photon emission
computer tomography (SPECT) of the head and neck was
performed 24 h after the injection. From the SPECT study,
5.3 mm thick transaxial, sagittal and coronal slices were re-
constructed.
Statistical analysis
In all analyses an autosomal dominant mode of inheritance
was assumed, with age dependent penetrance as described
elsewhere. Briefly, five age classes were defined (15-20 years,
20-30, 30-40, 40-50, and over 50 years of age) with pene-
trances of 10%, 35%, 65%, 90% and 95% respectively.
Likelihoods were calculated using version 5.03 of the Link-
age package of computer programs (Lathrop & Lalouel,
1984), with the frequency of the gene fixed at 0.0001. For the
likelihood calculations under genomic imprinting the pene-
trance in children of female gene carriers was assumed to be
0.0, irrespective of age.
Results
One member (V-25) underwent clinical examination but did
not have an MRI examination because of claustrophobia. In
this patient computed tomography of the head and neck was
performed instead. Individual IV-15, who is an obligate
carrier and may well have the disease subclinically, and three
of his five children who are at high risk of being affected,
refused MR or CT screening despite several requests. All
other participants completed the study.
Glomus tumours
Table I lists the clinical, hormonal and MR findings of the
affected family members with one or more tumours. Exam-
ination of medical records revealed two deceased members
(III-3, IV-18) in whom glomus tumours had been diagnosed
by means of angiography and surgery. In the family member
IV-4 who died from amyotrophic lateral sclerosis, no evi-
dence of glomus tumours had been found on previously
performed contrast enhanced CT examinations. The past
medical and familial history of relatives II-1, 11-2, III-1,
III-2 and IV-5 was not suggestive of the presence of
paragangliomas.
Clinical examination of the eight previously diagnosed
glomus tumour patients revealed no new tumours. Among
their relatives one (IV- 10) complained of unsteadiness which
she attributed to old age, but no tumours were found on
physical examination. In another relative (IV-20) who also
suffered from neurofibromatosis, bilateral carotid masses
were felt in the neck.
In the eight known patients, the MR examinations of the
head and neck demonstrated all previously diagnosed tum-
ours and in addition, two hitherto unrecognised glomus
tumours in two of the subjects (IV-17, V-13). In 6 undiag-
nosed relatives (IV-10, IV-13, IV-20, IV-22, V-64, V-66)
10 chemodectomas were found on MRI. In total MRI dem-
onstrated 20 glomus tumours comprising eight carotid body
tumours, three vagal body tumours and nine jugulotympanic
tumours. Of the 14 living patients seven had multicentric
lesions (50%). Tumour diameter ranged from 5 mm to
70 mm. A small vagal body tumour and a carotid body
tumour were not visible on CT, but were confirmed by
angiography.
In the patient with neurofibromatosis on MRI subcu-
taneous neurofibromas and a large skull lesion were found.
The latter proved to be a so-called 'lambdoid defect' on skull
roentgenograms (Resnick, 1989). Furthermore, in one rela-
tive, MRI showed a small cerebellar vascular malformation
that was considered to be a coincidental finding.
Functioning paragangliomas
All participants underwent the urinary screening tests. Only
one of the known patients (V- 19) had a history that was
indicative of a functioning paraganglioma, i.e. hypertension,
episodic headaches, palpitations and heavy perspiration. This
patient and two of the relatives (V- 12, V-64) were found to
have elevated urinary excretion of catecholamihes. In two
subjects (V-19, V-64) MRI and MIBG scintigraphy re-SCREENING FOR HEREDITARY PARAGANGLIOMAS 905
Table I Demographic, clinical and imaging findings ofparaganglioma patients
Pedigree Age at diag. Signs Endocrin. MRI Specials
identification Gender and symptoms findings findings Diagnosis remarks
A (111-3) 49 Puls. Tinitus N.A. N.A. GJT Bilat. Angiography
M Hearing loss and Surgery
B (IV-10)' 70 Vertigo Hyper- GJT GJT
F Unsteadiness tension
C (IV-II) 53 Hearing loss - GJT GJT
F
D (IV- 13)' 64 None - GJT GJT Bilat.
M GJT
E (IV- 16) 48 Hearing loss - GJT GJT
M
F (IV- 17) 45 Puls. Tinitus - GVT GVTa
M Cervical mass GCT GCT
G (IV- 18) 19 N.A. N.A. N.A. GJT Died abroad from intra-
F cranial extension GJT
H (IV-20)a 48 Cervical mass - GCT GCT Bilat. Cutaneous neurofibromas and
M Bilateral GCT Neurofibr. Lambda skull defect on MRI.
I (IV-22)- 43 None ? GCT GCT
M GJT GJT
J (V-11) 29 Vagal nerve lesion - GJT GJT
M Middle ear mass
K (V-12) 27 Cervical mass Catechol. GCT Function. MIBG uptake by GCT
M GCT
L (V-13) 25 Hearing loss - GJT GJT GVT not visible on CT,
F GVT GVTa confirmed by angiography
M (V-19) 26 Facial nerve lesion Hypert GJT GJT MIBG uptake by
M Middle ear mass Catechol. Pheo Pheoa left adrenal
N (V-64)a 31 None Catechol. GVT/GCTGVT/GCT MIBG uptake by right adrenal
M Hypert. Pheo Pheo GCT only visible on angiogram
0 (V-66)a 27 None - GCT GCT
M
P (V-67) 18 Cervical mass - OCT GCT
F
aNew patient or tumour diagnosis.
vealed an adrenal pheochromocytoma. After removal of the
pheochromocytomas catecholamine production normalised in
both patients. In the third person (V-12) there was a strong
MIBG uptake by a small carotid body tumour. No other
paragangliomas were present in this patient. On removal of
the carotid body tumour, catecholamine production returned
to normal. None of the others had signs or symptoms sugges-
ting a hormonally active tumour.
Hereditary aspects
The pedigree consisting of 99 family members older than 18
years showed a total of 16 patients with glomus tumours
(Figure 1). Pheochromocytomas were found twice in com-
bination with glomus tumours and did not occur separately.
Eleven men and five women were affected. In six previously
undiagnosed individuals the disease could be established by
means of MRI. Nine male gene carriers had 16 affected and
18 unaffected children. In the offspring (n = 15) of three
affected females no clinical evidence suggestive for paragang-
liomas or MRI abnormalities could be detected. In the 16
children of females who were at risk to be gene carrier no
abnormalities were found either. Likelihood calculations were
carried out to compare the regular autosomal dominant
mode of inheritance with the alternative explanation of
genomic imprinting. The results provide support for the
hypothesis of genomic imprinting with odds as high as
23375:1.
Discussion
The present study demonstrates that a considerable percen-
tage of hormonally active and non-active paragangliomas are
clinically occult both in known patients as well as in asymp-
tomatic family members. By MR imaging and catecholamine
testing we detected a number of new patients and new
tumours that would otherwise only have been diagnosed in a
much later stage or even not'at all. It is therefore apparent
that in the past, pedigrees of paraganglioma kindred groups
have been incomplete.
The new cases of glomus tumour that were detected in this
study occurred only in persons that had inherited the disease
gene from their father. Our new findings are completely
consistent with predictions based on the genomic imprinting
theory, i.e. the gene is transmitted by both men and women,
but only leads to disease manifestations when inherited via
the father. Given a complete autosomal dominant transmis-
sion by males, the three affected females should have had
seven or eight affected children, but they had none. These
observations are summarised in our statistical evaluation,
which provides convincing odds supporting the genomic im-
printing hypothesis.
On the basis of this theory and the high percentage of
asymptomatic patients found in our study, it can even be
speculated that a proportion of ostensibly sporadic glomus
tumours are in fact familial tumours that have been transmit-
ted over several generations by the maternal line or by male
patients with undetected tumours. A more accurate assess-
ment of the proportion of isolated cases can only be obtained
when the genetic defect has been characterised.
We dealt with a familial tumour syndrome. The common
characteristics of the familial tumours are increased risk to
the families of the patients, lower age of onset and multi-
plicity of tumours. The average age of tumour diagnosis in
non-familial patients is 42.5 years, compared with a mean
age at diagnosis of 38.8 years in our group (Grufferman et
al., 1980). In the fifth generation, in part due to our screening
efforts, tumours were even diagnosed at a much earlier age
(Table I). The more advanced age for tumour diagnosis in
non-familial patients is probably due to the lack of suspicion
and the initial absence of symptoms. Even in our group with
highly aware individuals some affected members had reached
an advanced age without any disturbing symptoms.
In the living patients, multiplicity (50%) and hormonal
activity (21%) was diagnosed in a considerably higher fre-
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Figure 1 Pedigree of investigated family: MR-normal MRI; MRna MRI not available; Aglomus tumour patient; dobligate
gene carrier; A possible gene carrier (female): BI functioning paraganglioma or pheochromocytoma; M neurofibromatosis;
El deceased family member.
1980; Dunn et al., 1986). This difference may entirely be
accounted for by the high sensitivity of MRI and consistent
testing for free urinary catecholamines with the highly ac-
curate HPLC technique Stein & Black, 1991). These proce-
dures were not used until recently.
As a screening method for paragangliomas, MRI proves to
be far superior to physical examination. Small glomus tu-
mours, in particular vagal and jugulo-tympanic tumours
escape clinical recognition altogether.
MRI offers several advantages compared with other diag-
nostic possibilities such as angiography, contrast enhanced
computed tomography and ['23I]MIBG scintigraphy that we
have discussed in a previous report (van Gils et al., 1991).
Moreover, MRI can detect chemodectomas smaller than
5 mm, while contrast enhanced CT only allows detection of
tumours greater than 8 mm (Vogl et al., 1989). In our group
this higher sensitivity of MRI was nicely illustrated by two
tumours which, because of their small size, could only be
confirmed by angiography and not by contrast enhanced CT.
Sequential MR examinations can provide insight into the
natural course of paragangliomas and provide essential in-
formation for genetic studies by exclusion of the disease in
unaffected persons or by detection of tumours in a very early
stage. A systematic search is currently under way to localise
the specific genetic defect in hereditary glomus tumours. MR
screening facilitates linkage analysis by increasing the number
of affected members.
At present there are no guide-lines for screening at-risk
relatives. Accurate risk assessment in family members
depends on assumptions about the mode of inheritance and
the role of genomic imprinting. Risk estimates for offspring
of females will be very much different if one takes into
account the possibility ofgenomic imprinting. When the gene
responsible for familial chemodectomas has been mapped,
further confirmation of the genomic imprinting theory will be
possible and accurate risk calculations will indicate family
members with a very high risk ofbeing gene carriers. Regular
MRI screening can be offered to those high risk subjects. The
absence of adverse side effects will be of major advantage as
it is necessary to follow these individuals for several years
given the metachronous tumour occurrence (Grimley, 1989).
Considering the fact that tumours are already found in
patients aged 18 to 25 and that morbidity and mortality are
directly related to size and extent of the tumour, it would
seem wise to initiate screening around the age of 20. Urine
analysis for catecholamines should always be included as
clinical symptoms suggestive for functioning tumours may be
sparse (van Gils et al., 1990). This paucity of symptoms and
the presence of only minimal biochemical abnormalities bears
a striking resemblance to the behaviour of pheoch-
romocytomas in MEN II (Stein & Black, 1991).
In the case of multiple paragangliomas and elevated cate-
cholamine levels, such as our cases V-19, and V-64, one is
not certain which tumour is active. In these cases MIBG
scintigraphy is invaluable to localise the functioning lesion
that has to be removed first (van Gils et al., 1990). One
patient showed cutaneous neurofibromas and a lambda de-
fect in the skull together with two carotid body tumours. The
association of neurofibromatosis with adrenal pheochromo-
cytomas is well known but the combination of neurofibro-
matosis and multicentric extra-adrenal paragangliomas has
only been reported once in English literature (DeAngelis et
al., 1987). A third case was found in German literature
(Loblich & Baumann, 1960). Although rare this combination
constitutes further evidence for Bolande's theory that both
disorders are neurocristopathies (Bolande, 1974).
In conclusion, by means of prospective screening with
MRI, this study provides further evidence for the theory that
inheritance of familial paragangliomas is subject to genomic
imprinting. When a paraganglioma is detected an extensive
search should be performed for additional tumours and
familial occurrence should be considered. For this purpose,
screening with MRI is the method of choice, not only
because it has no adverse side-effects, but also because of its
very high sensitivity. In keeping with our results in another
non-familial patient group hormonal activity was not an
infrequent finding in this patient group. Because symptoms
and signs are usually minimal, periodic examination of indi-
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viduals at risk will allow the detection of tumours and hor-
monal activity in a presymptomatic and still localised stage.
This in turn allows therapeutic intervention at an early stage
thus providing a basis for secondary prevention.
The authors thank Mr R. Byrne and Ms P. Roes for technical
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